This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Chemed (CHE) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 8.74% and 0.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak
by Zacks Equity Research
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
Here's Why Chemed (CHE) Should Remain in Your Portfolio Now
by Zacks Equity Research
Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Chemed's VITAS Business Strong, Weak Acuity Mix Shifts a Woe
by Zacks Equity Research
Chemed's (CHE) VITAS registers an expanded average daily census.
Why Is Chemed (CHE) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Q1 Earnings Miss Estimates, Revenues Grow Y/Y
by Zacks Equity Research
Despite several downsides, Chemed (CHE) witnesses solid revenue growth across key subsidiaries - VITAS and Roto-Rooter.
DGX vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) is expected to benefit from the launch of its VITAS Healthcare Inpatient Hospice Unit.
Here's Why You Should Hold on to DaVita (DVA) Stock Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, rising expenses remain a dampener.
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
These 5 Stocks Make Great Buys on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Why Is Chemed (CHE) Up 2.7% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured expert Kevin Matras highlights: Balchem, Methode Electronics, Chemed, Ubiquiti Networks and HEXO
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Balchem, Methode Electronics, Chemed, Ubiquiti Networks and HEXO
5 Stocks in Focus on New Analysts Coverage
by Zacks Equity Research
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
Chemed Gains Ground on Solid VITAS & Roto-Rooter Businesses
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries.
Chemed (CHE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Chemed's (CHE) Q4 revenues grow across key segments.
Chemed (CHE) Q4 Earnings Top Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 2.45% and -0.49%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EHC vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?